All In Biotech

Drug Trial Radar · NCT05130021

A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

130

Planned (sponsor's estimate)

Start

Jan 31, 2022

Primary completion

May 30, 2022

Study completion Oct 31, 2023

Sponsor

Lead sponsor
Maxinovel Pty., Ltd.Industry
Sponsor type
Industry
First posted
Nov 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • MAX-40279-01Drug

    MAX-40279-01 50mg/70mg

  • regorafenibDrug

    regorafenib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease control rate (DCR)[Part 1]Time frame: Through study Part 1 completion, an average of 6 months
  2. progress free survival(PFS)[Part 2]Time frame: Through study Part 1 completion, an average of 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.